APRE
HEALTHCAREAprea Therapeutics Inc
$0.83-0.01 (-1.15%)PRE
Live · NASDAQ · May 9, Close
AI Insight
What's Moving APRE Today?
No stock-specific AI insight has been generated for APRE yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$0.55$2.22
$0.83
Fundamentals
Market Cap$10M
P/E Ratio—
EPS$-1.93
Dividend Yield—
Dividend / Share—
ROE-0.7%
Profit Margin—
Debt / Equity—
Trading
Volume181K
Avg Volume (10D)—
Shares Outstanding12.4M
APRE News
20 articles- Oracle upgraded, Planet Fitness downgraded: Wall Street's top analyst callsYahoo Finance·May 7, 2026
- Aprea Therapeutics to Provide Clinical Update on ACESOT-1051 Phase 1 Trial Evaluating WEE1 Inhibitor, APR-1051, at ASCO 2026 Annual MeetingYahoo Finance·Apr 21, 2026
- Aprea Therapeutics Announces Closing of Oversubscribed $30 Million Private PlacementYahoo Finance·Apr 1, 2026
- Aprea Therapeutics Announces Oversubscribed $30 Million Private PlacementYahoo Finance·Mar 30, 2026
- Aprea Therapeutics Highlights Positive Emerging Clinical Activity for WEE1 Inhibitor, APR-1051, with a Confirmed Partial Response in the Ongoing Phase 1 ACESOT-1051 TrialYahoo Finance·Mar 30, 2026
- Aprea Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides a Corporate UpdateYahoo Finance·Mar 16, 2026
- Aprea Therapeutics Announces Additional Positive Clinical Activity for WEE1 Inhibitor, APR-1051, Including Second Partial Response in Ongoing ACESOT-1051 TrialYahoo Finance·Feb 18, 2026
- Aprea Therapeutics to Present at Oppenheimer 36th Annual Healthcare Life Sciences ConferenceYahoo Finance·Feb 17, 2026
- Aprea Therapeutics Strengthens Global Patent Portfolio in DNA Damage Response (DDR) Cancer Therapeutics, Paving Way for Pipeline GrowthYahoo Finance·Feb 12, 2026
- Aprea Therapeutics Appoints Industry Veteran Eugene Kennedy, MD, as Chief Medical AdvisorYahoo Finance·Feb 4, 2026
- BC-Most Active StocksYahoo Finance·Jan 30, 2026
- Aprea Therapeutics Announces Early Clinical Proof-Of-Concept in the Ongoing ACESOT-1051 Dose-Escalation Trial Evaluating WEE1 Inhibitor APR-1051, Including Partial Response Observed on First ScanYahoo Finance·Jan 29, 2026
- Aprea Therapeutics Announces $5.6 Million Private Placement Priced At-The-Market Under Nasdaq RulesYahoo Finance·Jan 29, 2026
- New Strong Sell Stocks for January 19thYahoo Finance·Jan 19, 2026
- New Strong Sell Stocks for Jan. 14Yahoo Finance·Jan 14, 2026
- Aprea Therapeutics CEO Issues Letter to Shareholders Highlighting Pipeline Progress in 2025 and Outlook for 2026Yahoo Finance·Dec 18, 2025
- Aprea Therapeutics Announces $3.1 Million Private Placement Priced At-The-Market Under Nasdaq RulesYahoo Finance·Dec 9, 2025
- Aprea Therapeutics Reports Third quarter 2025 Financial Results and Provides a Clinical UpdateYahoo Finance·Nov 12, 2025
- Aprea Therapeutics Provides Clinical Update from ACESOT-1051 Trial Showing Early Signals of Activity for WEE1 Kinase Inhibitor APR-1051Yahoo Finance·Oct 24, 2025
- Aprea Therapeutics Establishes Recommended Phase 2 Dose (RP2D) for ATRN-119, Considering Combination TherapiesYahoo Finance·Oct 15, 2025
All 20 articles loaded
Price Data
Open$0.79
Previous Close$0.84
Day High$0.82
Day Low$0.79
52 Week High$2.22
52 Week Low$0.55
52-Week Range
$0.55$2.22
$0.83
Fundamentals
Market Cap$10M
P/E Ratio—
EPS$-1.93
Dividend Yield—
Dividend / Share—
ROE-0.7%
Profit Margin—
Debt / Equity—
Trading
Volume181K
Avg Volume (10D)—
Shares Outstanding12.4M
About Aprea Therapeutics Inc
Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and markets cancer therapies that reactivate the mutant p53 tumor suppressor protein. The company is headquartered in Boston, Massachusetts.
HEALTHCAREBIOTECHNOLOGY
Company Details
Security TypeStock
ExchangeNASDAQ
CurrencyUSD
Round Lot—
SICBIOTECHNOLOGY
CIK—
Composite FIGI—
Share Class FIGI—